Clinical trials: Normal Healthy
Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered single and multiple doses of EDP-978 in…
- Trial name
- NCT07540910
- Testing
- EDP-978
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Healthy Subjects
A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole
This study will be conducted in healthy post-menopausal female subjects to assess the pharmacokinetics (PK) of Camizestrant (AZD9833) when administered alone and in combination with Itraconazole.
- Trial name
- NCT05551897
- Testing
- Camizestrant, Itraconazole
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Atopic Dermatitis
A Study to Determine the Safety & Efficacy of ZPL-5212372 in Healthy Subjects and in Subjects With Atopic Dermatitis
A Randomised, Adaptive Design, Double-Blind (3rd Party Open), Placebo Controlled, Sequential Group Study to Determine the Safety,Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of a Topical ZPL-5212372…
- Trial name
- NCT02795832
- Testing
- ZPL-5212372 1% w/w Ointment BID
- Where
- 3 sites in United Kingdom
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Ziarco Pharma Ltd
Healthy
Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)
The purpose of the study is to determine the relative pharmacodynamic effects and safety of crushed and whole ALO-01 compared to MSIR and to Placebo, and of crushed ALO-01 to whole ALO-01; to determine the relative…
- Trial name
- NCT00751478
- Testing
- ALO-01, MSIR
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Acne Vulgaris
W0265-103: A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0% - Tretinoin 0.025% Gel (Ct Gel) In Healthy Volunteers
Clindamycin 1.0% - tretinoin 0.025% gel (CT Gel) is a reformulation of VELAC Gel that contains the same active ingredients (clindamycin 1.0% and tretinoin 0.025%) in a modified vehicle.
- Trial name
- NCT01929278
- Testing
- CT Gel (clindamycin 1% and tretinoin 0.025%), Vehicle gel patch, Blank patch
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Stiefel, a GSK Company
Pruritus
Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls
This is a phase 1, open-label, single-dose study in adults with moderate hepatic impairment (defined as Child-Pugh B cirrhosis) and matched healthy control participants with normal hepatic function.
- Trial name
- NCT05393076
- Testing
- Linerixibat
- Where
- 2 sites in United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning
In this study, radioactive PF-06427878 will be administered, through a vein, alone and with 2 different oral doses of non-radioactive PF-06427878 to healthy, adult, male subjects.
- Trial name
- NCT02410525
- Testing
- [11C]PF-06427878, PF-06427878 10 mg, PF-06427878 600 mg
- Where
- 3 sites in United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study To Evaluate The Effect Of Food On How Tasocitinib (CP-690,550) Is Absorbed And Moves Through The Body Following Oral Administration Of Tasocitinib (CP-690,550) Tablets To Healthy Subjects
In this study, a 10 mg tasocitinib (CP-690,550) tablet will be administered to healthy subjects on two separate dosing occasions.
- Trial name
- NCT01184001
- Testing
- Treatment A, Treatment B
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Systemic Lupus Erythematosus, Rheumatoid Arthritis
A Phase I Study of ICP-022 in Healthy Subjects
This is a single center, randomized, double-blind, placebo-controlled, dose escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ICP-022 following oral single and…
- Trial name
- NCT03189017
- Testing
- ICP-022
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Innocare Pharma Australia Pty Ltd
Cystic Fibrosis, Pulmonary
Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single doses of ARO-ENaC in healthy adult volunteers; and to evaluate the safety, tolerability, PK and efficacy of multiple doses of…
- Trial name
- NCT04375514
- Testing
- ARO-ENaC
- Where
- 7 sites in Australia, New Zealand
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Healthy Adult Participants, Hepatic Impairment (HI)
A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic Function
This is a single-center, non-randomized, open-label, parallel-group study. It will test D-2570 in people with liver problems and in people with healthy livers, to see how the drug moves through the body and whether it is safe.
- Trial name
- NCT07715149
- Testing
- D-2570
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- InventisBio Co., Ltd
Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female
Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia
This is a first-in-human study of ABS-201, a new investigational medicine, in healthy adult men and women. Its main purpose is to find out whether ABS-201 is safe and well tolerated, as well as to understand how the body…
- Trial name
- NCT07317544
- Testing
- SAD IV Dose 1 - 150mg ABS201 IV Single Dose, ABS-201 SC Multiple Doses
- Where
- 5 sites in Australia
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Absci Pty Ltd.
Psoriasis
Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects
Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis. A total of approximately 24 subjects will be randomized into 3 cohorts(15mg, 30mg, 60mg), approximately 8 healthy…
- Trial name
- NCT03570346
- Testing
- Hemay005
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tianjin Hemay Bio-Tech Co., Ltd
Psoriasis
Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis
The purpose of this study is to establish if BMS-986202 is safe and effective at treating autoimmune diseases such as psoriasis.
- Trial name
- NCT02763969
- Testing
- BMS-986202, Interferon alpha-2a recombinant, Famotidine
- Where
- 2 sites in Australia
- Volunteers
- 357 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Endometriosis, Uterine Fibroids
A Trial of SHR7280 in Healthy Subjects
The study is being conducted to evaluate the effect of high-fat meal on pharmacokinetics of SHR7280 after oral administration and the effect of SHR7280 on QT interval at low and high doses in healthy Chinese volunteers.
- Conditions
- Endometriosis, Uterine Fibroids, Assisted Reproduction
- Trial name
- NCT06969664
- Testing
- SHR7280 Tablet
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Cardiac Effects in Normal Healthy Volunteers
A Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers
The purpose of this study is to determine if the study drug, ACHN-490 Injection, affects the QT interval in normal volunteers. The hypothesis is that the drug will not cause an increase in the QT interval.
- Trial name
- NCT01514929
- Testing
- ACHN-490 Injection, Moxifloxacin
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Achaogen, Inc.
Psoriasis, Atopic Dermatitis
A Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis
Evelo will investigate the safety and tolerability of EDP1815 and its potential to be a medicinal product in healthy volunteers and individuals with mild to moderate psoriasis and atopic dermatitis.
- Trial name
- NCT03733353
- Testing
- EDP1815
- Where
- 9 sites in United Kingdom
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Evelo Biosciences, Inc.
Atopic Dermatitis, Psoriasis
Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma
This Phase 1 study will investigate the safety and tolerability of EDP1867 in healthy volunteers, participants with atopic dermatitis, and, optionally, in participants with psoriasis and/or asthma.
- Conditions
- Atopic Dermatitis, Psoriasis, Asthma
- Trial name
- NCT04927195
- Testing
- EDP1867
- Where
- 7 sites in United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Evelo Biosciences, Inc.
Healthy, Rheumatoid Arthritis
Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects
This is a Phase 1, randomized, double-blind, placebo-controlled study designed in 3 parts to assess the safety, tolerability, and PK of single and multiple ascending doses of FPA008 in adult healthy volunteers (Parts 1 and 2) and…
- Trial name
- NCT01962337
- Testing
- FPA008
- Where
- 6 sites in Hungary, Netherlands and 1 more
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Five Prime Therapeutics, Inc.
Pharmacokinetic Differences, Y-3
Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects
The goal of this clinical trial is to assess the pharmacokinetic profiles and safety of Y-3 in subjects with mild hepatic insufficiency (Child-Pugh: grade A), moderate hepatic insufficiency (Child-Pugh: grade B) and gender, age…
- Conditions
- Pharmacokinetic Differences, Y-3, Saftey, Mild Hepatic Insufficiency
- Trial name
- NCT07055412
- Testing
- Y-3 for injection（40mg）
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Neurodawn Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.